login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
ABIVAX SA-ADR (ABVX) Stock News
USA
-
Nasdaq
- NASDAQ:ABVX -
US00370M1036
-
ADR
125.71
USD
+6.59 (+5.53%)
Last: 11/24/2025, 8:00:00 PM
125.8
USD
+0.09 (+0.07%)
After Hours:
11/24/2025, 8:00:00 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ABVX Latest News, Press Relases and Analysis
All
Press Releases
6 days ago - By: Benzinga
- Mentions:
CAH
ELAN
GH
MEDP
...
6 Healthcare Stocks With Strong Upward Momentum
7 days ago - By: The Motley Fool
- Mentions:
AMLX
CGON
COGT
CNTA
This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead
7 days ago - By: The Motley Fool
- Mentions:
LQDA
CGON
COGT
AMLX
...
This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch
2 months ago - By: Benzinga
Why Is Abivax Stock Trading Higher On Monday?
11 days ago - By: Zacks Investment Research
Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's What You Should Know
11 days ago - By: Zacks Investment Research
- Mentions:
CPRX
Are Medical Stocks Lagging Abivax SA Sponsored ADR (ABVX) This Year?
21 days ago - By: Abivax
Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis
21 days ago - By: Abivax
Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis
2 months ago - By: Investor's Business Daily
- Mentions:
AAPL
Top 1% Biotech Abivax Surges On 'Compelling' Results In A Highly Watched Disease
2 months ago - By: Abivax
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
2 months ago - By: Abivax
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
2 months ago - By: Abivax
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
2 months ago - By: Abivax
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
2 months ago - By: Abivax
Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
2 months ago - By: Abivax
Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
2 months ago - By: Abivax
Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
2 months ago - By: Abivax
Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
2 months ago - By: Abivax
Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
2 months ago - By: Abivax
Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
3 months ago - By: Abivax
Abivax Presents First Half 2025 Financial Results
3 months ago - By: Abivax
Abivax Presents First Half 2025 Financial Results
4 months ago - By: Abivax
Abivax Announces Closing of $747.5 Million Public Offering
4 months ago - By: Abivax
Abivax Announces Closing of $747.5 Million Public Offering
4 months ago - By: Abivax
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
4 months ago - By: Abivax
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
4 months ago - By: Abivax
Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
4 months ago - By: Abivax
Abivax announces trading resumption of its ordinary shares on Euronext Paris
4 months ago - By: Abivax
Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
4 months ago - By: Abivax
Abivax announces trading resumption of its ordinary shares on Euronext Paris
Please enable JavaScript to continue using this application.